

---

# ***Different Types of Partnerships Which Compose PDPs for Improved Global Health***

***Business Development Track***

***Thursday, 21 May 2009, 2:00 – 3:30 PM***

***Georgia World Congress Center – Room B313***



# Different Types of Partnerships Which Compose PDPs for Improved Global Health

## Panelists



**Nina Grove**

**VP, Program Management and Development**



**Jean-Pierre Paccaud**

**Director of Business Development**



**Philippe Farabolini**

**Director, Business Development Access to Medicines**



**David P. Perry**

**Chief Executive Officer**

---

## Moderator



**Paul Nakagaki**

**Group Research Strategy**

# Format for Today's Panel Discussion

## *A focus on lessons learned*

- **Introduction and Context:** 40 minutes
  - Setting the Scene Paul Nakagaki
  - iOWH Nina Grove
  - DNDi Jean-Pierre Paccaud
  - Sanofi Aventis Philippe Farabolini
  - Anacor David Perry
- **Panel Discussion:** 30 minutes
- **Audience Q&A:** 20 minutes


# A Fatal Imbalance

## *What is the “right” amount of new drugs?*

An estimated 1 bio people, or 1/6 the global population, are infected with one or more neglected tropical diseases (NTD)

Tropical diseases (including malaria) and tuberculosis account for 12% of the global disease burden

Only 1.3% of new drugs developed over the past 30 years address NTDs



**21 new drugs for neglected diseases (including 8 for malaria and 3 for tuberculosis):**  
**1.3%**

# The “90/10 Gap”

## *And what is the “right” level of investment?*

“In 1990...only about 5% of the world's resources for health research (which totaled US\$ 30 billion in 1986) were being applied to the health problems of developing countries, where 93% of the world's burden of ‘preventable mortality’ occurred. Some years later, the term ‘10/90 gap’ was coined to capture this major imbalance between the magnitude of the problem and the resources devoted to addressing it.

“...global expenditure on health research has more than quadrupled to over US\$ 125 billion in 2003;

“...the term ‘10/90 gap’, while not representing a current quantitative measure, has become a symbol of the continuing mismatch between needs and investments.”

*Global Forum for Health Research*

# What's Needed to Combat Neglected Tropical Diseases (NTDs)?

## Large scale interventions

- Lymphatic filariasis
- Leprosy
- Onchocerciasis
- Schistosomiasis
- Helminthiasis
- Trachoma
- Yaws



**Rapid Impact Interventions**  
*Improving access*

## Case management and development of new tools


- Human African trypanosomiasis
- Chagas diseases
- Buruli ulcer
- Leishmaniasis
- Dengue



**Focused interventions**  
*Improving innovation*

# Success Rates and Cost of Development

*Global health cannot afford to be like pharma*



# Relationships in Global Health

*Complex environment and multiple partnerships*

